GLP-1 News — Week of July 13, 2026
The GLP-1 stories that mattered this week — each one summarised neutrally and linked to its primary source. Nothing here is influenced by advertisers.
FDA declares national tirzepatide injection shortage resolved, raising pressure on compounders
The FDA has determined that the national shortage of tirzepatide injections is resolved, meaning supply of brand-name Mounjaro and Zepbound is now considered adequate. This improves the odds that your pharmacy can fill branded prescriptions, but it also makes it more likely that regulators will crack down on pharmacies that continue to compound tirzepatide without a shortage-based justification, which could shrink access to lower-cost compounded versions. (2026-07-16)
Source: FDA via Medriva
Related on Metabolic Ledger: /regulatory/fda-compounding-cliff
Large BMJ network meta-analysis ranks weight-loss drugs by effect and outcomes
A BMJ systematic review and network meta-analysis of 262 trials found the greatest one-year average weight loss with tirzepatide, CagriSema, oral semaglutide, orforglipron, and injectable semaglutide compared with lifestyle changes alone. However, only injectable semaglutide currently has moderate-to-high certainty evidence for reducing major cardiovascular events and death, which may influence how you and your clinician weigh weight loss, heart protection, and cost when choosing a drug. (2026-07-09)
Source: The BMJ
Related on Metabolic Ledger: /drugs/best-glp1-for-weight-loss
BMJ perspective warns that stopping GLP-1 drugs often leads to meaningful weight regain
A BMJ editorial reviewing trial data concludes that patients commonly regain a substantial share of lost weight after stopping GLP-1 therapy, with average regain around 4–5 kg in studied populations. The authors emphasize that obesity is a chronic condition and that GLP-1s are likely to be long-term, possibly lifelong treatments, so you should plan ahead for ongoing cost, access, and side-effect management rather than expecting a short course to give permanent weight loss. (2026-07-04)
Source: The BMJ
Related on Metabolic Ledger: /after-glp1/weight-regain-after-glp1
NEJM phase 3 trial shows setmelanotide can significantly reduce BMI in hypothalamic obesity
In a phase 3 NEJM trial of people with acquired hypothalamic obesity, daily setmelanotide led to an average 16.5 percent reduction in BMI over 52 weeks, compared with a 3.3 percent BMI increase on placebo, and also improved hunger scores. Although it is not a GLP-1, this MC4R agonist highlights an alternative pathway for rare, severe forms of obesity where GLP-1s may be less effective, offering potential options for patients with hypothalamic injury after tumors or surgery. (2026-07-08)
Source: NEJM
STAT investigation finds inconsistent and sometimes lax GLP-1 telehealth prescribing
A STAT report on a Yale-led secret-shopper study of nearly 50 GLP-1-focused telehealth sites describes uneven medical evaluations, limited screening for contraindications, and aggressive, sales-like marketing practices. For you as a patient, the findings underscore the need to choose telehealth services that take full histories, order labs when appropriate, and provide follow-up care, especially when compounded and off-label GLP-1 products sit in a gray regulatory area. (2026-07-06)
Source: STAT
Related on Metabolic Ledger: /providers/compare